
A stent can restore blood flow to the heart, but in people with stable coronary disease, it may offer no added protection against heart attacks or early death.
For someone told they have a narrowed heart artery, opening it can seem like the obvious next step. Yet improving blood flow and preventing future health problems are separate goals, and a procedure that achieves one may not necessarily achieve the other.
Researchers led by Neel Butala, MD, of the University of Colorado Anschutz, examined that question through an extended follow-up of participants in the COURAGE trial. They found no statistically significant difference in the combined risk of death or heart attack between patients initially assigned to an artery-opening procedure plus medical therapy and those assigned to medical therapy alone.
Published in JAMA and presented at the 2026 American Heart Association Scientific Sessions, the findings offer an unusually long look at how these treatment strategies compare.
What The Long-Term Stent Study Found
The original COURAGE trial enrolled people with stable coronary artery disease and compared optimal medical therapy alone with optimal medical therapy plus percutaneous coronary intervention (PCI), commonly known as angioplasty.
During angioplasty, doctors inflate a small balloon inside a narrowed artery to improve blood flow. They often place a tiny metal tube called a stent to help keep the artery open.
For the new analysis, researchers tracked 959 participants through linked health records. The median follow-up was 15 years, with some patients followed for as long as 25 years. The estimated 25-year cumulative incidence of death or heart attack was 93.3% in the group initially assigned to PCI plus medical therapy and 91% in the medical therapy group. That difference was not statistically significant.
Earlier research had examined long-term survival after the trial. This analysis also included heart attacks, allowing researchers to assess whether an initial PCI strategy might prevent cardiovascular events that would not be captured by survival figures alone.
Better Blood Flow Does Not Guarantee Longer Life
The central finding concerns what happens after an artery has been successfully opened. Restoring blood flow can relieve symptoms, but the study did not find evidence that starting with PCI lowered the combined long-term risk of heart attack or death.
“When we open a blocked artery, we know we’ve improved blood flow through that artery, and that relieves symptoms. But the bigger question is whether that translates into a reduction in clinical events such as heart attacks or death for patients over the long term. That’s what we wanted to understand with this study,” said Butala, an assistant professor of medicine-cardiology at the CU Anschutz School of Medicine.
“We found no significant difference in the risk of death or heart attack between the two treatment groups. That’s important information for doctors and patients as they consider the best approach to treating stable coronary artery disease.”
These results do not mean angioplasty and stents are unnecessary. They can relieve chest pain and other symptoms, while emergency procedures can be lifesaving during certain types of heart attacks. The study specifically examined an initial PCI strategy for stable coronary disease, so its findings should be understood within that setting.
How To Interpret The Findings
Although the participants came from a randomized trial, this analysis was a post hoc observational follow-up, rather than a new randomized trial. It included veterans whose health records could be linked, a group with higher baseline health risks than the full COURAGE trial population.
The researchers also acknowledged limitations in identifying heart attacks through routinely collected health records. However, the findings were consistent with events independently verified during the original trial.
The research helps clarify what an initial procedure may accomplish. Symptom relief remains a meaningful benefit, but the long-term findings do not establish additional protection against heart attack or death compared with medical therapy alone. Butala said considering both immediate relief and future health outcomes can support more informed treatment decisions.
Reference: “Percutaneous Coronary Intervention and Long-Term Outcomes in Stable Coronary Artery Disease: Extended Follow-Up of the COURAGE Randomized Trial” by Neel M. Butala, Nandini Murali, Natalia Rahman, Shayna Cave, Siamack Ayandeh, Mary E. Plomondon, Jonathan W. Cunningham, William S. Weintraub, Robert W. Yeh, Stephen W. Waldo and William E. Boden, 7 November 2026, JAMA.
DOI: 10.1001/jama.2026.23488
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.